Atea Pharmaceuticals, Inc. has filed an updated Schedule 13G/A with the SEC, revealing important changes in beneficial ownership. This filing, dated November 13, 2026, highlights the stakes held by JPM Partners LLC and Jean-Pierre Sommadossi, shedding light on the company's shareholder structure and potential future direction.

Background

Atea Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker AVIR. Recently, Atea has been active in filing various reports, including a 10-Q and multiple 8-K forms, indicating ongoing business developments.

What the Filing Says

The Schedule 13G/A filing reveals that JPM Partners LLC holds 5,116,025 shares of Atea's common stock, representing 6.4% of the company. Jean-Pierre Sommadossi, who is the manager of JPM Partners LLC, beneficially owns an additional 3,964,425 shares, which includes stock options. Together, Sommadossi's total beneficial ownership amounts to 9,080,450 shares, or 11% of Atea's common stock.

Impact

This update may affect various stakeholders, including current and potential investors, as it showcases significant ownership by key individuals and entities. The filing indicates a level of confidence in Atea's future prospects, which may influence investor sentiment in the pharmaceutical preparations sector.

What's Next

The filing does not say what happens next.